A novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia
Prof. Francisco Cervantes
Anemia is a frequent manifestation of myelofibrosis (MF), and there is an unmet need for effective treatments in anemic MF patients. The multinational REALISE phase 2 study evaluated a novel dosing strategy for ruxolitinib in these patients. The results reinforce the notion that is is unnecessary to delay or withhold ruxolitinib because of co-existent or treatment-emergent anemia.
